Yeh‐Fong Chen

1.3k total citations
17 papers, 1.0k citations indexed

About

Yeh‐Fong Chen is a scholar working on Statistics and Probability, Pharmacology and Economics and Econometrics. According to data from OpenAlex, Yeh‐Fong Chen has authored 17 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Statistics and Probability, 6 papers in Pharmacology and 5 papers in Economics and Econometrics. Recurrent topics in Yeh‐Fong Chen's work include Statistical Methods in Clinical Trials (8 papers), Treatment of Major Depression (6 papers) and Health Systems, Economic Evaluations, Quality of Life (5 papers). Yeh‐Fong Chen is often cited by papers focused on Statistical Methods in Clinical Trials (8 papers), Treatment of Major Depression (6 papers) and Health Systems, Economic Evaluations, Quality of Life (5 papers). Yeh‐Fong Chen collaborates with scholars based in United States, United Kingdom and Canada. Yeh‐Fong Chen's co-authors include John R. Johnson, Rajeshwari Sridhara, Martin H. Cohen, Richard Pazdur, Ni A. Khin, Thomas Laughren, Peiling Yang, Yang Yang, Hung Hung and Yang Yang and has published in prestigious journals such as Clinical Cancer Research, Statistics in Medicine and The Journal of Clinical Psychiatry.

In The Last Decade

Yeh‐Fong Chen

16 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yeh‐Fong Chen United States 10 354 306 239 198 134 17 1.0k
Angelika Caputo Switzerland 14 353 1.0× 59 0.2× 316 1.3× 135 0.7× 137 1.0× 39 1.6k
Hélène M. Faessel United States 23 362 1.0× 195 0.6× 87 0.4× 1.1k 5.7× 48 0.4× 52 1.9k
Christine Alvey United States 22 259 0.7× 107 0.3× 202 0.8× 268 1.4× 252 1.9× 46 1.4k
C. Puozzo France 23 689 1.9× 274 0.9× 314 1.3× 322 1.6× 153 1.1× 47 1.5k
Martin Johnson United States 15 285 0.8× 320 1.0× 49 0.2× 138 0.7× 140 1.0× 38 760
Christopher Kaiser United States 18 157 0.4× 66 0.2× 86 0.4× 89 0.4× 270 2.0× 35 856
Paul Gilman United States 14 1.1k 3.1× 273 0.9× 118 0.5× 197 1.0× 71 0.5× 37 1.8k
Cathie Leister United States 17 284 0.8× 300 1.0× 34 0.1× 523 2.6× 31 0.2× 31 1.1k
Hans‐Peter Beck‐Bornholdt Germany 18 268 0.8× 497 1.6× 135 0.6× 160 0.8× 142 1.1× 63 1.4k
Bradford R. Hirsch United States 17 290 0.8× 171 0.6× 76 0.3× 187 0.9× 33 0.2× 42 1.2k

Countries citing papers authored by Yeh‐Fong Chen

Since Specialization
Citations

This map shows the geographic impact of Yeh‐Fong Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yeh‐Fong Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yeh‐Fong Chen more than expected).

Fields of papers citing papers by Yeh‐Fong Chen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yeh‐Fong Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yeh‐Fong Chen. The network helps show where Yeh‐Fong Chen may publish in the future.

Co-authorship network of co-authors of Yeh‐Fong Chen

This figure shows the co-authorship network connecting the top 25 collaborators of Yeh‐Fong Chen. A scholar is included among the top collaborators of Yeh‐Fong Chen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yeh‐Fong Chen. Yeh‐Fong Chen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Chen, Yeh‐Fong, et al.. (2022). Challenges and potential strategies utilizing external data for efficacy evaluation in small-sized clinical trials. Journal of Biopharmaceutical Statistics. 32(1). 21–33. 2 indexed citations
2.
Chen, Yeh‐Fong, et al.. (2022). Consideration of the adaptive randomization allocation ratio in the presence of treatment group heteroscedasticity in clinical trials. Journal of Biopharmaceutical Statistics. 32(3). 511–526.
3.
Zhang, Xiangmin, Yeh‐Fong Chen, & Roy Tamura. (2017). The plan of enrichment designs for dealing with high placebo response. Pharmaceutical Statistics. 17(1). 25–37. 3 indexed citations
4.
Teng, Zhaoyang, Yeh‐Fong Chen, & Mark Chang. (2017). Unified additional requirement in consideration of regional approval for multiregional clinical trials. Journal of Biopharmaceutical Statistics. 27(6). 903–917. 3 indexed citations
5.
Filozof, Claudia, Shein‐Chung Chow, Lara Dimick‐Santos, et al.. (2017). Clinical endpoints and adaptive clinical trials in precirrhotic nonalcoholic steatohepatitis: Facilitating development approaches for an emerging epidemic. Hepatology Communications. 1(7). 577–585. 48 indexed citations
6.
Kong, Fanhui & Yeh‐Fong Chen. (2016). Testing treatment effect in schizophrenia clinical trials with heavy patient dropout using latent class growth mixture models. Pharmaceutical Statistics. 15(4). 349–361. 2 indexed citations
7.
Tamura, Roy, Jeffrey P. Krischer, Christian Pagnoux, et al.. (2015). A small n sequential multiple assignment randomized trial design for use in rare disease research. Contemporary Clinical Trials. 46. 48–51. 27 indexed citations
8.
Chen, Yeh‐Fong, Xiangmin Zhang, Roy Tamura, & Chiung M. Chen. (2014). A sequential enriched design for target patient population in psychiatric clinical trials. Statistics in Medicine. 33(17). 2953–2967. 10 indexed citations
9.
Chen, Yeh‐Fong, Thomas Laughren, Paul A. David, et al.. (2014). Review of Maintenance Trials for Major Depressive Disorder. The Journal of Clinical Psychiatry. 75(3). 205–214. 88 indexed citations
10.
Khin, Ni A., Yeh‐Fong Chen, Yang Yang, Peiling Yang, & Thomas Laughren. (2012). Exploratory Analyses of Efficacy Data From Schizophrenia Trials in Support of New Drug Applications Submitted to the US Food and Drug Administration. The Journal of Clinical Psychiatry. 73(6). 856–864. 63 indexed citations
11.
Khin, Ni A., Yeh‐Fong Chen, Yang Yang, Peiling Yang, & Thomas Laughren. (2011). Exploratory Analyses of Efficacy Data From Major Depressive Disorder Trials Submitted to the US Food and Drug Administration in Support of New Drug Applications. The Journal of Clinical Psychiatry. 72(4). 464–472. 168 indexed citations
12.
Chen, Yeh‐Fong, Yang Yang, Hung Hung, & Sue‐Jane Wang. (2011). Evaluation of performance of some enrichment designs dealing with high placebo response in psychiatric clinical trials. Contemporary Clinical Trials. 32(4). 592–604. 64 indexed citations
13.
Khin, Ni A., Yeh‐Fong Chen, Yang Yang, Peiling Yang, & Thomas Laughren. (2011). Dr Khin and Colleagues Reply. The Journal of Clinical Psychiatry. 72(9). 1284–1285. 2 indexed citations
14.
Chen, Yeh‐Fong, et al.. (2010). Trial design issues and treatment effect modeling in multi‐regional schizophrenia trials. Pharmaceutical Statistics. 9(3). 217–229. 38 indexed citations
15.
Kong, Fanhui, Yeh‐Fong Chen, & Kun Jin. (2009). A Bias Correction in Testing Treatment Efficacy Under Informative Dropout in Clinical Trials. Journal of Biopharmaceutical Statistics. 19(6). 980–1000. 1 indexed citations
16.
Cohen, Martin H., John R. Johnson, Yeh‐Fong Chen, Rajeshwari Sridhara, & Richard Pazdur. (2005). FDA Drug Approval Summary: Erlotinib (Tarceva®) Tablets. The Oncologist. 10(7). 461–466. 351 indexed citations
17.
Johnson, John R., Martin H. Cohen, Rajeshwari Sridhara, et al.. (2005). Approval Summary for Erlotinib for Treatment of Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer after Failure of at Least One Prior Chemotherapy Regimen. Clinical Cancer Research. 11(18). 6414–6421. 179 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Angelika Caputo Breakdown of academic impact, for papers by Hélène M. Faessel Breakdown of academic impact, for papers by Christine Alvey Breakdown of academic impact, for papers by C. Puozzo Breakdown of academic impact, for papers by Martin Johnson Breakdown of academic impact, for papers by Christopher Kaiser Breakdown of academic impact, for papers by Paul Gilman Breakdown of academic impact, for papers by Cathie Leister Breakdown of academic impact, for papers by Hans‐Peter Beck‐Bornholdt Breakdown of academic impact, for papers by Bradford R. Hirsch
Rankless by CCL
2026